Abcam, ab263119, Human C12orf10 knockout HeLa cell lysate

Size: 1Kit
MYG1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 7 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 7 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MYG1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
C12orf10 also known as MGC54262 is a protein encoded by the C12orf10 gene. The protein has a molecular mass of approximately 20 kDa. It is expressed in several tissues with notable expression in the liver and kidney. Mechanically C12orf10 is involved in intracellular processes although detailed mechanisms are not yet fully understood. The protein localizes within the cytoplasm and may play a role in cellular transport or signaling given its distribution.
Biological function summary
C12orf10 participates in cellular processes that regulate cell growth and differentiation. While not yet fully characterized as part of a larger complex it may interact with other proteins involved in signal transduction. These interactions suggest that C12orf10 could influence cellular communication and the response to extracellular signals. The precise biological implications remain an active area of research aiming to reveal more about how it affects cellular functions.
Pathways
C12orf10 seems to be involved in pathways that pertain to cellular signaling and metabolic regulation. Specifically it likely interacts within the MAPK pathway where it may link to proteins like MEK1/2 which are important in transmitting signals from the cell membrane to the nucleus. This pathway affects cell fate decisions which highlights the role of C12orf10 in cell proliferation and survival. Another potential pathway is the insulin signaling pathway where C12orf10 might influence glucose metabolism highlighting its role in energy balance and cellular homeostasis.
C12orf10 has been associated with metabolic disorders such as diabetes due to its involvement in glucose regulation pathways. The protein's potential interaction with insulin receptor substrate proteins makes it a point of interest in understanding insulin resistance and metabolic syndrome. Additionally there is emerging evidence linking C12orf10 to certain liver diseases including non-alcoholic fatty liver disease (NAFLD). This connection may involve interactions with proteins like AMPK which are important regulators of energy homeostasis and lipid metabolism. Further research is needed to clarify these associations and the therapeutic potential of targeting C12orf10 in these conditions.